<DOC>
	<DOCNO>NCT00325156</DOCNO>
	<brief_summary>To assess safety reactogenicity DTPa-IPV/Hib vaccine primary booster vaccination . The DTPa-IPV/Hib vaccine give 3 4 month age co-administered GSK Biologicals ' rotavirus vaccine Placebo . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Assess Safety &amp; Reactogenicity DTPa-IPV/Hib Vaccine Administered 3 , 4 , 5 &amp; 18 Mths Age , Healthy Infants</brief_title>
	<detailed_description>Single group study . Subjects GSK Biologicals ' rotavirus study ( Rota-028 ) Singapore enrol study . 3-4-5 month schedule booster dose 18 month</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion Subjects must enrol Rota028 study . A male female , include , 11 17 week age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Subjects investigator believe parents/guardians comply requirement protocol Exclusion criterion Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Any confirmed suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>11 Weeks</minimum_age>
	<maximum_age>17 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>